Long-term open-label tofacitinib extension study in moderate to severe ulcerative colitis

Phase 3, open-label trial of tofacitinib in autoimmune colitis (2 arms), sponsored by Pfizer. Primary endpoints: Incidence and severity of adverse events and No primary efficacy endpoint. Started Aug 2013; status: active, not recruiting.